Phase 2 N=33 Radiotherapy for Solid Tumor Spine Metastases
Solid Tumor Spine Metastases
Primary: Number of Participants With Radiographic Recurrence at 12 Months — 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=36 Stereotactic Body Radiotherapy for Spine Tumors
Spinal Metastases · Vertebral Metastases · Benign Spinal Tumors
Primary: Initial Symptom Control — 3; 28; 3; 27 Participants
Phase 2 N=35 Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis
Metastatic Cancer · Pain · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Pain Response as Measured by VAS at 3 Months — 8; 12; 1 Participants
Phase 3 N=46 Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis
Metastatic Cancer · Pain
Primary: Percentage of Patients Receiving Radiosurgery/SBRT Per Protocol or With Minor Variation (Phase II) — 39; 37 Participants
N/A N=51 Spinery® A Novel Radio-Frequency Tumor Ablation Device for Spine Metastatic Tumors
Vertebral Metastasis
Primary: Change From Baseline in Worst Pain and Quality of Life Scores at 3 Months Using the Brief Pain Inventory (BPI) and EQ-5D-5L Questionnaires — 3.4; 65.2 points on a…
N/A N=24 Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery
Melanoma · Metastatic Malignant Neoplasm in the Spine · Renal Cell Carcinoma
Primary: Distance Between the Gross Disease and Spinal Cord (Cord-disease Distance, CDD) of at Least 3mm After Treatment. — 1; 14 Participants
Phase 2 N=71 Evaluation of Single Session Stereotactic Body Radiotherapy
Spinal Neoplasms
Primary: Complete Pain Relief Using Stereotactic Body Radiotherapy (SBRT) to Treat Spine and Para- Spinal Tumors in a Single Session — 18 Participants
N/A N=21 Stereotactic Body Radiation Therapy (SBRT) for Tumors Near the Spinal Cord
Spinal Tumors
Primary: Toxicity — 14; 0; 0; 0 participants
N/A N=10 Pilot Study of Same-session MR-only Simulation and Treatment With Stereotactic MRI-guided Adaptive Radiotherapy (SMART) for Oligometastases of the Spine
Oligometastases of the Spine
Primary: Number of Participants to Receive Delivery of the First Fraction of Same-session MRI-only Simulation and Treatment With SMART on the First On-table Attempt — 8…
Phase 3 N=16 Randomized Study Comparing Local Tumor Control After Post-Operative Single-Fraction or Hypofractionated Stereotactic Radiosurgery in the Treatment of Spinal Metastases
Spinal Metastases
Primary: Local Tumor Control Using MRI or CT
N/A N=44 High-precision Radiotherapy of Motor Deficits Due to Metastatic Spinal Cord Compression
Spinal Cord Compression Due to Metastasis to Spine
Primary: Number of Participants Who Were Alive at 6 Months After Radiotherapy Without Deterioration of Motor Function During (or Directly After) Radiotherapy and Freedom From…
N/A N=203 Radiotherapy of Motor Deficits From Metastatic Epidural Spinal Cord Compression
Metastatic Epidural Spinal Cord Compression
Primary: Number of Participants Showing Improvement or no Further Progression of Motor Deficits at 1 Month Following Radiotherapy — 68; 69 Participants
N/A N=229 Study Comparing Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy (CRT) for Spinal Metastases
Spinal Metastases
Primary: Phase III: Complete Pain Response at 3 Months Post-radiation — 16; 40; 29; 20 Participants — p=0.0002
N/A N=22 Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc
Neoplasm Metastasis
Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants
N/A N=40 Stereotactic Radiation Therapy in Treating Patients With Brain Metastases
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Proportion of Patients Dying of Neurological Death, Defined as Dying With Progressive Neurological Dysfunction Regardless of Systemic Disease Status — 5 patients
N/A N=29 Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
N/A N=30 Image-guided Cryoablation of Head, Neck and Spine Tumors
Head and Neck Neoplasms · Malignant Neoplasm of Vertebral Column
Primary: Number of Participants Undergoing Image-guided Cryoablation of a Head, Neck, or Spine Tumor With Adverse Events — 3; 0 participants
Phase 2 N=51 Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Brain Metastasis · Bladder Cancer · Breast Cancer
Primary: Local Control — 13; 23; 2; 1 participants
N/A N=545 Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
N/A N=43 A Phase II Study of Spinal Radiosurgery
Neoplasm · Arteriovenous Malformations
Primary: Number of Participants With Palliative Response (Pain or Relief of Neurologic Symptoms) From Single Fraction Radiosurgery Delivered With Tomotherapy — 29 Participants
N/A N=22 PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer
Metastatic Prostate Cancer
Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants
N/A N=128 A Study For Using Radiosurgery On Limited Metastases
Neoplasms, Metastatic
Primary: Percentage of Curatively Treated Patients With Progression-free Survival — 16 percentage of participants
Phase 2 N=28 Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
N/A N=13 A Dose Escalation Trial of Five Fraction Stereotactic Radiation Therapy for Brain Metastases
Brain Metastases
Primary: Maximum Tolerated Dose of Five Fraction Stereotactic Radiotherapy — 35; 30 Gy
Phase 3 N=129 Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8 · Metastatic Breast Carcinoma · Metastatic Malignant Neoplasm in the Bone
Primary: Progression-free Survival (Phase II) — 23.0; 19.5 months — p=0.36
Phase 3 N=213 Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
Breast Cancer · Cognitive/Functional Effects · Lung Cancer
Primary: Neurocognitive Progression as Measured by the Number of Participants With Cognitive Deterioration by 3 Months — 40; 44 Participants — p=<0.001
N/A N=70 Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers
Sarcoma · Thoracic Cancer · Abdominal Cancer
Primary: Rate of Local Control — 29 Participants
N/A N=41 A Proof-of-principle Study of HBO-SRS for Brain Metastases
Brain Metastases
Primary: The Average Time From HBO Chamber Exit to SRS beam-on — 8.3 minutes
N/A N=24 Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis
Metastatic Malignant Neoplasm to Brain · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Maximum Tolerated Dose (MTD) of Hypofractionated Radiosurgery Defined as the Highest Dose Level Where a Grade 3 or Greater With an Attribution Score of ≥ 3 Develops in ≤…
N/A N=69 Dorsal Root Ganglion Thermal Radiofrequency Versus Pulsed Radiofrequency for Metastatic Pain in Thoracic Vertebral Body
Bone Neoplasm,Malignant Vertebral Column Thoracic Secondary
Primary: The European Organisation for Research and Treatment of Cancer (EORTC) Questionnaire to Measure Change in the Intensity of Pain QLQ-C30 — 41.30; 51.08; 38.76; 42.48…